Lab/path equity participation: when buying in actually pays
Group path practices offer buy-in tracks that come with valuations, K-1 income, and a long lock-up. Here’s the framework for evaluating one.
Author: Pouyan Golshani
Founder of GigHz. Physician, builder, and deep-tech advisor exploring the intersections of advanced materials, medicine, and market strategy. I help innovators refine ideas, connect to the right stakeholders, and bring meaningful solutions to life — one signal at a time.
Tax planning for pathologists: high-volume W-2 with rare practice equity
Most pathologists are W-2 with no practice equity. The optimization conversation defaults to entity structure, real estate, and retirement stacking.
Real estate for nuclear medicine physicians
High W-2 income, often with imaging center K-1 supplement, is the perfect substrate for real estate depreciation. Here’s the stack.
AI tools for nuclear medicine: dictation, quantification, and theranostic dosing
Nuclear medicine AI is moving from research to clinic. Here’s the working tool stack for modern nuclear physicians.
Tax planning for nuclear medicine physicians: high W-2 + theranostic K-1
If you have theranostic procedure income through a partnership, the tax structure is different. Here’s what to model.
Imaging center ownership for nuclear medicine physicians
PET/SPECT imaging center ownership is more accessible than CT/MRI. Here’s the financial model and the regulatory considerations.
Theranostics economics: how PSMA and DOTATATE are reshaping nuclear medicine reimbursement
Theranostic radiopharmaceuticals are creating new procedure code volumes and ownership opportunities. Here’s the rate data and the operator economics.
Retirement vehicle stacking for lab medicine physicians
Cash balance plans, defined benefit overlays, mega backdoor Roth — most lab/path physicians stop at 401(k) max. The stack matters.
AI in clinical chemistry and microbiology: signal vs. noise
Lab medicine AI is moving fast. Here’s the directory of tools that have actual deployment data, not just press releases.
Lab equity participation: when a buy-in offer is actually worth it
Group lab buy-in offers come with valuations, K-1 income, and exit timing. Here’s the framework before you write the check.